409 related articles for article (PubMed ID: 20177404)
21. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
Boennelycke M; Thomsen BM; Holck S
Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
[TBL] [Abstract][Full Text] [Related]
22. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.
Sasaki Y; Akasu T; Saito N; Kojima H; Matsuda K; Nakamori S; Komori K; Amagai K; Yamaguchi T; Ohue M; Nagashima K; Yamada Y
Cancer Sci; 2016 Jul; 107(7):1006-12. PubMed ID: 27089049
[TBL] [Abstract][Full Text] [Related]
24. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome.
Heijink DM; de Vries EG; Koornstra JJ; Hospers GA; Hofstra RM; van Vugt MA; de Jong S; Kleibeuker JH
Crit Rev Oncol Hematol; 2011 Nov; 80(2):264-77. PubMed ID: 21159521
[TBL] [Abstract][Full Text] [Related]
25. DNA Mismatch Repair-Deficient Colorectal Carcinoma: Referral Rate for Genetic Cancer Risk Assessment in a Brazilian Cancer Center.
Gomes AAD; Macedo MP; Torrezan GT; Zenun GR; Aguiar S; Begnami MD; Carraro DM; Formiga MN
J Gastrointest Cancer; 2021 Sep; 52(3):997-1002. PubMed ID: 32974876
[TBL] [Abstract][Full Text] [Related]
26. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
[TBL] [Abstract][Full Text] [Related]
27. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.
Ricker CN; Hanna DL; Peng C; Nguyen NT; Stern MC; Schmit SL; Idos GE; Patel R; Tsai S; Ramirez V; Lin S; Shamasunadara V; Barzi A; Lenz HJ; Figueiredo JC
Cancer; 2017 Oct; 123(19):3732-3743. PubMed ID: 28640387
[TBL] [Abstract][Full Text] [Related]
28. [Microsatellite instability. A new predictive marker (?)].
Dietmaier W
Pathologe; 2010 Oct; 31 Suppl 2():268-73. PubMed ID: 20824433
[TBL] [Abstract][Full Text] [Related]
29. Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.
Hemminger JA; Pearlman R; Haraldsdottir S; Knight D; Jonasson JG; Pritchard CC; Hampel H; Frankel WL
Hum Pathol; 2018 Aug; 78():125-130. PubMed ID: 29723603
[TBL] [Abstract][Full Text] [Related]
30. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
[TBL] [Abstract][Full Text] [Related]
31. Microsatellite instability in the management of colorectal cancer.
Pino MS; Chung DC
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):385-99. PubMed ID: 21651356
[TBL] [Abstract][Full Text] [Related]
32. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways.
Sánchez-de-Abajo A; de la Hoya M; van Puijenbroek M; Tosar A; López-Asenjo JA; Díaz-Rubio E; Morreau H; Caldes T
Clin Cancer Res; 2007 Oct; 13(19):5729-35. PubMed ID: 17908962
[TBL] [Abstract][Full Text] [Related]
33. Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression.
Lee-Kong SA; Markowitz AJ; Glogowski E; Papadopoulos C; Stadler Z; Weiser MR; Temple LK; Guillem JG
Clin Colorectal Cancer; 2010 Oct; 9(4):255-9. PubMed ID: 20920999
[TBL] [Abstract][Full Text] [Related]
34. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.
Clendenning M; Huang A; Jayasekara H; Lorans M; Preston S; O'Callaghan N; Pope BJ; Macrae FA; Winship IM; Milne RL; Giles GG; English DR; Hopper JL; Win AK; Jenkins MA; Southey MC; Rosty C; Buchanan DD;
Fam Cancer; 2018 Jan; 17(1):91-100. PubMed ID: 28616688
[TBL] [Abstract][Full Text] [Related]
35. Colorectal cancer due to deficiency in DNA mismatch repair function: a review.
Bellizzi AM; Frankel WL
Adv Anat Pathol; 2009 Nov; 16(6):405-17. PubMed ID: 19851131
[TBL] [Abstract][Full Text] [Related]
36. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
[TBL] [Abstract][Full Text] [Related]
37. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of Mismatch Repair Protein Testing on Outcome of Early Staged Colorectal Carcinomas.
Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
40. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
Lin AY; Lin E
J Hematol Oncol; 2015 Nov; 8():124. PubMed ID: 26542241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
